Teleflex Inc Stock Price, News & Analysis

Teleflex Incorporated (NYSE: TFX) will feature its Chairman, President, and CEO, Liam Kelly, at the 43rd Annual Raymond James Institutional Investors Conference. The event will be held on March 8, 2022, at 9:15 a.m. ET in Orlando, FL. A live audio webcast and accompanying slide presentation will be accessible on Teleflex's investor website. As a leading provider of medical technologies, Teleflex aims to improve health and quality of life through innovative solutions across various fields such as vascular access, anesthesia, and emergency medicine.

Teleflex (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share, payable on March 15, 2022, to shareholders recorded by March 7, 2022. This dividend reflects the company's commitment to providing value to its investors while operating in the medical technology sector. Teleflex focuses on diverse medical solutions aimed at improving health outcomes globally, with a strong emphasis on innovation and addressing unmet clinical needs.

Teleflex reported fourth quarter revenues of $761.9 million, reflecting a 7.1% year-over-year increase. The GAAP diluted EPS was $2.69, up from $1.62, while adjusted diluted EPS rose to $3.60, marking a 10.8% increase. For 2022, the company expects GAAP revenue growth of 2.3% to 3.8% and adjusted EPS between $13.70 and $14.30. The respiratory divestiture is projected to affect growth, contributing a 1.6% headwind. Teleflex emphasized its strategy for sustainable growth and enhancement of margins amid operational challenges.

Teleflex has received FDA clearance for expanded use of its specialty catheters and coronary guidewires in chronic total occlusion percutaneous coronary interventions (CTO PCI). CTOs, affecting nearly 20% of patients, are significant blockages that lead to ischemia. The CTO-PCI study demonstrated a 93.3% technical success rate and over 75% procedural success, emphasizing the effectiveness of Teleflex's devices in complex cases. This advancement reflects Teleflex's commitment to innovative medical technologies that enhance patient outcomes.

Teleflex (NYSE: TFX) will host a conference call on February 24, 2022, at 8:00 a.m. Eastern Time to discuss its fourth quarter and full year 2021 financial results. Investors can register for the call via the provided link or access it through an audio webcast on Teleflex's website. A replay will be available later that day. Teleflex specializes in medical technologies aimed at enhancing health and quality of life through innovative solutions across various medical fields, including vascular access and emergency medicine.

Teleflex is set to have its Chairman, President, and CEO, Liam Kelly, speak at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 4:30 p.m. ET. The event will be accessible via a live audio webcast on the Teleflex investor relations website, along with presentation slides. Known for its innovative medical technologies aimed at improving health outcomes, Teleflex operates in diverse fields including vascular access, interventional cardiology, and emergency medicine. Further details can be found on their website.

Teleflex Incorporated has received reimbursement approval for its UroLift System to treat benign prostatic hyperplasia (BPH) in Japan, effective April 1, 2022. This minimally invasive procedure offers symptom relief and improved quality of life for men suffering from BPH. CEO Liam Kelly emphasized the strategic investment in UroLift's commercial capabilities in Japan, aiming to train medical staff by early 2022. The UroLift System, already used in over 300,000 cases worldwide, is expected to significantly benefit the over two million affected men in Japan.

Teleflex Incorporated (NYSE: TFX) has announced a worldwide recall of its Arrow-Trerotola™ Over-The-Wire PTD® Kit due to a defect where the inner lumen can detach from the device’s basket. This recall affects products manufactured between October 2019 and July 2021, classified as a Class I recall by the FDA. The company received seven complaints, with no reported long-term complications. Consumers are advised to discontinue use and return all affected products. The recall notice, including product codes and lot numbers, is available on their website.

Teleflex (NYSE: TFX) has been named the top large company in the MedReps.com Best Places to Work in Medical Sales 2022 survey. This marks the fifth consecutive year Teleflex has earned this honor. The survey, which included over 2,300 medical sales professionals, highlighted key factors such as pay, leadership, and culture as significant for employees when choosing an employer. Teleflex's leadership expressed pride in the award, emphasizing the company's commitment to innovation and employee engagement.